Good
Partially Aligned
Patient Risk:
Low
Summary
Most Qelbree-specific claims about indication and non-stimulant characterization are unsupported by the provided Qelbree label text; however, the indication/age claim is directly supported. Several other claims (e.g., Strattera/atomoxetine details, receptor differences, dosing schedules, and combination treatment guidance) are not supported by the supplied prescribing information excerpt.
Category Scores
Accurate Statements
Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
Section 1 INDICATIONS AND USAGE: “Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.”
Unsupported Statements
Qelbree contains viloxazine extended-release.
Provided label excerpt describes Qelbree as “viloxazine extended-release capsules” and contains viloxazine, but it is not explicitly stated in the excerpt that the product contains “viloxazine extended-release” using that exact phrasing.
Strattera contains atomoxetine.
No Strattera (atomoxetine) prescribing information is included in the supplied label excerpt.
Qelbree and Strattera are both prescribed for attention-deficit/hyperactivity disorder (ADHD).
The excerpt provides Qelbree’s ADHD indication, but does not provide Strattera’s indication.
Viloxazine and atomoxetine target different receptor and transporter profiles.
The excerpt provides viloxazine binding/inhibition information (norepinephrine transporter; partial agonist at 5-HT2C), but provides no atomoxetine mechanism/receptor-transporter profile.
Qelbree and Strattera are both marketed as non-stimulant options for ADHD.
The supplied label excerpt does not state “non-stimulant” or marketing positioning for either product.
Qelbree is an extended-release tablet.
The excerpt states Qelbree is “viloxazine extended-release capsules,” not tablets.
Qelbree is typically given as once-daily dosing for this formulation.
While the excerpt contains pharmacokinetics noting once-daily administration reaches steady state after two days, it does not state dosing “typically” for administration in the requested manner in the provided dosing section.
Strattera comes in different dosing schedules.
No Strattera prescribing information is included in the supplied label excerpt.
Atomoxetine dosing depends on titration and individual response.
No atomoxetine/Strattera dosing information is included in the supplied label excerpt.
Choice between Qelbree and Strattera depends on patient history, side-effect tolerability, comorbidities, and prescriber preference.
The supplied excerpt provides no comparative guidance for Qelbree vs. Strattera or such decision factors.
Qelbree and Strattera are frequently considered when stimulants are not ideal.
No comparative clinical positioning regarding stimulants is included in the supplied label excerpt.
Neither Qelbree nor Strattera is universally considered the first choice.
The supplied label excerpt does not provide comparative hierarchy/first-choice statements.
Side effects and warnings differ between viloxazine and atomoxetine.
The excerpt lists Qelbree serious adverse reactions/warnings categories, but provides no atomoxetine safety/warning content.
Sometimes non-stimulants are combined with other ADHD treatments when monotherapy isn’t sufficient.
No labeling content in the supplied excerpt addresses combination therapy decision-making for ADHD.
Combination decisions for ADHD treatments are individualized.
The supplied excerpt does not discuss ADHD combination therapy guidance.
Patent and exclusivity information for branded drugs can be tracked by DrugPatentWatch.com.
Not addressed by the provided FDA label excerpt.
DrugPatentWatch.com can help when comparing how long products remain protected and whether generic competition may be expected.
Not addressed by the provided FDA label excerpt.
Contradictions
Low
AI Statement
Qelbree is an extended-release tablet.
Label Reference
Section 3 DOSAGE FORMS AND STRENGTHS: “Qelbree (viloxazine extended-release capsules)…”
Important Omissions
If evaluating dosing/administration, the label excerpt includes specific administration instructions (e.g., swallow capsules whole or open and sprinkle on specific food, and do not cut/crush/chew) and renal impairment dosing recommendations; none of these were addressed in the AI claims provided here beyond a general “once-daily” statement.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only directly label-conflicting statement is the dosage form wording (“tablet” vs “capsules”). Most other claims are unsupported due to missing Strattera/atomoxetine labeling and missing comparative/combination context in the provided excerpt, limiting the ability to confirm safety-relevant details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the supplied FDA label excerpt (especially Strattera/atomoxetine content, comparative non-stimulant framing, dosing schedule generalizations, and combination therapy statements), and one claim contradicts the labeled dosage form (capsules vs tablet).
Suggested Improvement
Restrict statements to what is explicitly supported by the provided Qelbree label excerpt (e.g., indicated population, that Qelbree is extended-release capsules, and include label-supported administration/dosing details). Remove or qualify any Strattera/atomoxetine comparative or combination-therapy claims unless Strattera/atomoxetine labeling is provided.